Details
Stereochemistry | RACEMIC |
Molecular Formula | C27H28N2O7 |
Molecular Weight | 492.5204 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC\C=C\C3=CC=CC=C3
InChI
InChIKey=KJEBULYHNRNJTE-DHZHZOJOSA-N
InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+
Molecular Formula | C27H28N2O7 |
Molecular Weight | 492.5204 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Optical Activity | ( + / - ) |
DescriptionSources: http://adis.springer.com/drugs/800001274Curator's Comment: Description was created based on several sources, including
http://www.nevapress.com/cdr/full/17/4/341.pdf | https://www.ncbi.nlm.nih.gov/pubmed/19426250
Sources: http://adis.springer.com/drugs/800001274
Curator's Comment: Description was created based on several sources, including
http://www.nevapress.com/cdr/full/17/4/341.pdf | https://www.ncbi.nlm.nih.gov/pubmed/19426250
Cilnidipine (FRC-8653) is a dihydropyridine (DHP) type of calcium channel antagonist. The L-type Ca2+ channel blockade by cilnidipine affects predominantly vascular smooth muscle, thereby producing vasodilation of peripheral resistance vessels and coronary arteries. The blockade of N-type Ca2+ channels affects predominantly peripheral nerve endings of sympathetic neurons, thereby dilating blood vessels by lowering plasma catecholamine levels. Furthermore, renoprotective and neuroprotective effects as well as cardioprotective action of cilnidipine have been demonstrated in clinical practice or animal examinations. Cilnidipine was originated by Fuji & Rebio Pharmaceutical Co., Ltd. and developed jointly with Ajinomoto for the treatment of hypertension. Cilnidipine has been launched in Japan.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
4.77 null [pIC50] | |||
6.08 null [pIC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ATELEC Approved UseHypertension |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10841896 |
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.eapharma.co.jp/en/news/2013/1213.pdf
Normally once daily 5 to 10 mg of cilnidipine after breakfast orally for
adult patient. The dose can be increased or reduced according to the
age and symptoms. If the above dose is not effective enough, the dose
can be increased to 20 mg once daily. For severe hypertension, 10 to 20
mg of cilnidipine orally once daily after breakfast.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19650875
Cell viability of PC12 was not affected by low concentrations of cilnidipine up to 150 uM, but it was slightly decreased at 200 uM cilnidipine.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:31:16 GMT 2023
by
admin
on
Fri Dec 15 16:31:16 GMT 2023
|
Record UNII |
97T5AZ1JIP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC08CA14
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
||
|
WHO-ATC |
C08CA14
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C065927
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
132203-70-4
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
102106-21-8
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
C171754
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
m3548
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
5282138
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
97T5AZ1JIP
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
642
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
7767
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
DTXSID0046309
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
100000091319
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
Cilnidipine
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
CHEMBL452076
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
SUB06268MIG
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
6880
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
DB09232
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY | |||
|
31399
Created by
admin on Fri Dec 15 16:31:16 GMT 2023 , Edited by admin on Fri Dec 15 16:31:16 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |